ArticleCommunications biology2026
Oxidative base damage to telomeres sensitizes cancer cells to ATR inhibition.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Targeted inhibition of DNA damage response proteins has received significant clinical attention owing to the success of PARP inhibitors. Due to G1/S checkpoint inactivation, cancer cells are reliant on the G2/M checkpoint to cope with elevated DNA replication stress. We demonstrated that a single induction of 8-oxo-guanine at telomeres in cancer cells was sufficient to induce replication stress but was not cytotoxic. Here, we find inhibition of ATR, CHK1, or WEE1 after induction of telomeric 8-oxo-guanine significantly reduced cell viability by inducing genome instability. This occurred at doses markedly less than those required to increase instability in non-cancerous cells. We determined the mechanism of this instability is due to insufficient levels of RPA for damaged telomeres, forcing cells to progress through S-phase with telomere damage and exit G2-phase prematurely, prolonging mitosis. This study demonstrates targeted oxidative base damage at telomeres can enhance the therapeutic efficacy of ATR inhibition in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.